COVID-19 Response

The Oxford BioDynamics facility remains operational and is continuing to provide biomarker support for clinical trials worldwide during this challenging period.

EpiSwitch™ selected for prognostic and predictive profiling of COVID-19 patients. 

Read more…

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

To learn more about our EpiSwitchTM technology and services for our clients in US, Europe and Asia, read our White Papers

Our Publications on EpiSwitch™

Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

Hunter, E., et. al.,
Translational Medicine Communications (2020) 5:5

March 25, 2020

https://doi.org/10.1186/s41231-020-00054-1

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P143.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P143_multitherapy.pdf

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P142.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf

Ectopic gene deregulations and chromosome conformations: integrating novel molecular testing into clinical applications, from leukemias to gliomas

Grand, FH., et. al.,
Handbook of Biomarkers and Precision Medicine

April 8, 2019

https://www.crcpress.com/Handbook-of-Biomarkers-and-Precision-Medicine/Carini-Fidock-Gool/p/book/9781498762588

Epigenetic chromatin conformation changes in peripheral blood can detect thyroid cancer.

Yan et. al.,
Surgery

November 8, 2018

https://doi.org/10.1016/j.surg.2018.05.081

Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington’s disease.

Salter, M., et. al.,
F1000Research 2018, 7:1757

November 7, 2018

https://doi.org/10.12688/f1000research.15828.1

Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis.

Salter et. al.,
EBioMedicine

June 25, 2018

https://doi.org/10.1016/j.ebiom.2018.06.015

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen, K.
EBioMedicine

June 25, 2018

https://doi.org/10.1016/j.ebiom.2018.06.015

Chromosome conformation signatures as a clinical tool for diagnosis, prognosis and disease understanding in ALS

Salter, M., et. al.,
ENCALS

June 22, 2018

https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2018-ENCALS-Chromosome-conformation-signatures-as-a-clinical-tool-for-diagnosis-prognosis-and-disease-understanding-in-ALS.pdf

White blood cells from Prostate cancer patients carry distinct Chromosome Conformations.

Pchejetski, D., et. al.
J of Urology

May 22, 2018

https://www.jurology.com/article/S0022-5347(18)40436-3/pdf